There has been interest in the use of dopaminergic agonists in patients with treatment resistant depression (TRD), although they have only been assessed in small-scale, short-term studies. We conducted a substantial RCT examining the effect and safety/tolerability of the dopamine agonist pramipexole in patients with TRD, the PAX-D trial. In this talk I will present the efficacy and safety results from the trial.
This seminar is hosted in person and online, to join online, please use the Zoom details below:
zoom.us/j/93598736019?pwd=tHJ65nmXIrmYTUhi7YRbbdlnyi5Ie6.1
Meeting ID: 935 9873 6019
Passcode: 897963